Crown Bioscience

Search from cancer cell lines and cell line-derived xenograft (CDX) models available for screening and faster in vitro to in vivo study translation.

High-quality, homogeneous tumor microarrays (TMAs) designed to provide researchers with samples for comprehensive cancer research, biomarker discovery, and drug target validation.

The world’s largest commercially available collection of patient-derived xenograft models featuring 2,500 PDX in vivo tumor models available for efficacy testing.

Patient-derived xenograft organoids that combine the flexibility of in vitro testing with the clinical relevance of PDX models, creating a translatable bridge for oncology drug development.

Unique collection of patient-relevant organoid models (PDXO) featuring associated histopathology, IC 50, genomic, and transcriptomic analysis data derived using IP-protected Hubrecht Organoid Technology protocols.

A highly translatable screening assay for evaluating monotherapy and combination drug responses in patient tumors with endogenous immune cell populations intact.

Cutting edge ex vivo bone marrow niche models designed for AML and multiple myeloma drug screening in a physiologically relevant setting.

Advanced 3D in vitro BMN models accurately replicating the complex bone marrow microenvironment to enable screening for hematological malignancies.

Patient Derived Xenograft (PDX) model for colorectal cancer derived from a moderately differentiated adenocarcinoma of the colon.

Patient Derived Xenograft (PDX) model for colorectal cancer derived from a metastatic poorly differentiated adenocarcinoma of the liver.

Patient-derived xenograft model for breast cancer.

Breast Cancer Tumor Microarrays derived from PDX for H&E and IHC staining, formalin-fixed and embedded in paraffin.

Pretreated ovarian cancer patient-derived xenograft model with pleural fluid biopsy and rare atypical cells positive for high-grade serous carcinoma.

Ovarian cancer patient-derived xenograft model with metastatic pathology diagnosis from a right perihepatic mass.

Humanized mouse model developed for evaluating CD3-based bispecific antibodies and T cell redirecting therapies targeting human CD3.

Fully humanized genetically modified mouse model designed for assessing CD3-based bispecific antibodies and BiTE efficacy in vivo.

Colon cancer humanized PBMC mouse model utilizing NOD/SCID strains for CD3-bispecific antibody and EpCAM BiTE testing.

Colon cancer humanized PBMC mouse model utilizing NCG/NOG/NPG strains.

Single Knock-In mouse model on a C57BL/6 background for immuno-oncology research.

Single Knock-In mouse model on a C57BL/6 background for immuno-oncology research.

An extensive collection of patient-derived xenograft (PDX) tumor models for preclinical cancer therapy evaluation and drug discovery.

Rapidly review, compare, and select translational oncology models, including PDX, cell line derived xenografts, and syngeneic models.

An organoid banking and screening platform allowing simultaneous testing across multiple models to support drug discovery and biomarker analysis.

Proprietary patient-derived organoid models offering reproducibility, standardized assays, and unmatched turnaround time for oncology drug development.

Preclinical models derived from GEMM or carcinogen-induced tumors harboring clinically-relevant oncogenic driver mutations, passaged solely in vivo.

A preclinical drug testing platform based on precision cut cancer tissue slices (PCCTS) for investigating anti-cancer drug effects in the natural tumor microenvironment.

Mouse models with fully intact immune systems widely used for immuno-oncology efficacy, biomarker, and pharmacodynamic studies.

Pretreated colorectal cancer patient-derived xenograft model with prior capecitabine, FOLFOX, and FOLFIRI treatments.

Pretreated colorectal cancer patient-derived xenograft model with liver metastasis.

High Throughput In Vivo screen platform to evaluate immune modulating agents across preselected panels of well-characterized syngeneic and tumor homograft models.

Patient-derived organoid systems providing physiologically relevant insights into drug efficacy, featuring OrganoidXplore for high-throughput screening.

Pretreated colorectal cancer patient-derived xenograft model derived from liver biopsy with a history of FOLFOX and FOLFIRI treatments.

Pretreated non-small cell lung cancer (NSCLC) patient-derived xenograft model with prior pemetrexed, carboplatin, and nivolumab treatment.

Pretreated colorectal cancer patient-derived xenograft model derived from liver with KRAS mutation and PD-L1 expression.

Screening services to detect therapeutic responses to compounds, antibodies, growth factors, and combinations including activity, toxicity, synergy, and mode of action using models seeded in a hydrogel.

Pretreated colorectal cancer patient-derived xenograft model derived from small bowel biopsy with prior FOLFIRI and Avastin treatment.

Pretreated colorectal cancer patient-derived xenograft model derived from left lung lingula biopsy with extensive multi-line therapy history.

Pretreated lung cancer patient-derived xenograft model with NRAS mutation and prior platinum-based and paclitaxel therapies.

Pretreated colorectal cancer patient-derived xenograft model derived from retroperitoneal biopsy with multiple lines of prior therapy.

PDAC PDX collection supporting in vivo efficacy studies, resistance modeling, and biomarker research across clinically relevant molecular subtypes.

Broaden possibilities with syngeneic, GEMM, tumor homograft models, and humanized genetically modified mouse models to enhance immunology outcomes.

Pretreated lung cancer patient-derived xenograft model featuring KRAS G12C mutation and PD-L1 expression.

Advanced tumor models such as orthotopic implantation with imaging, tumor homografts, and other niche platforms tailored for specific efficacy questions.

Lung cancer homograft model featuring moderately differentiated adenocarcinoma with KRAS and P53 mutations on a C57BL/6 background.

Preclinical humanized immunotherapy platforms featuring genetically modified mouse models and engineered tumor cells expressing humanized drug targets and ligands for in vivo efficacy evaluation.

Lung cancer homograft model featuring moderately differentiated adenocarcinoma with KRAS and PTEN mutations on a C57BL/6 background.

Pretreated pancreatic cancer patient-derived xenograft model linked to patient PA9573.

Lung cancer homograft model featuring osteosarcoma with PTEN and P53 mutations on a C57BL/6 background.

A non-small cell lung cancer cell line-derived xenograft model containing an adenocarcinoma cell line with an activating EGFR mutation in exon 19 and high PD-L1 expression, used for evaluating immunotherapeutics and overcoming drug resistance.

Lung cancer homograft model featuring osteosarcoma with P53 mutation on a C57BL/6 background.

Lung cancer homograft model featuring poorly to moderately differentiated adenocarcinoma on a C57BL/6 background.

Patient Derived Xenograft (PDX) model for liver cancer, specifically hepatocellular carcinoma grade II-III.

Pretreated lung cancer patient-derived xenograft model with retroperitoneal lymph node metastasis and multiple immunotherapy lines.

Patient Derived Xenograft (PDX) model for liver cancer, specifically hepatocellular carcinoma grade II-III.

Patient Derived Xenograft (PDX) model for colorectal cancer derived from transverse colon adenocarcinoma.

Breast cancer homograft model featuring papillary adenocarcinoma on an FVB/N background with MMTV-PyVT TG mutation.

Lung cancer homograft model induced by urethane on a BALB/c background.

Head and neck cancer homograft model featuring neuroendocrine carcinoma on a BALB/c background.

Pretreated mesothelioma patient-derived xenograft model derived from pleural fluid.

Bladder cancer homograft model derived from GEMM with KRAS G12D and PTEN Flox/Flox mutations on a C57BL/6 background.

Brain cancer homograft model featuring Glioblastoma on a C57BL/6 background.

Immune-competent models that preserve core PDAC biology, well suited for immuno-oncology, stromal biology, and combination studies.

Lung cancer homograft model induced by urethane featuring moderately differentiated adenocarcinoma on a BALB/c background.

Patient Derived Xenograft (PDX) model for liver cancer, specifically right lobes massive type hepatocellular carcinoma.

Comprehensive preclinical evaluation services for CAR-T and cell therapies, integrating in vitro, ex vivo, and in vivo platforms to assess efficacy, safety, and persistence.

Patient Derived Xenograft (PDX) model for Head and Neck Cancer, derived from tongue moderately differentiated squamous cell carcinoma.

Patient-derived xenograft model for lung cancer.

Lung cancer patient-derived xenograft model from lung tissue collection.

Patient Derived Xenograft (PDX) model for liver cancer, specifically hepatocellular carcinoma, featuring chronic cholecystitis and specific IHC and viral status characteristics.

Patient-derived xenograft model for brain cancer.

Syngeneic tumor cell lines engineered with human ligand expression for modeling dual interactions between tumor and immune components.

Lung cancer syngeneic model on C57BL/6 mouse strain with immune cell profiling and RNAseq data available.

Patient-derived xenograft model for liver cancer.

Colorectal cancer syngeneic model on C57BL/6 mouse strain with immune cell profiling and RNAseq data available.

Lung cancer patient-derived xenograft model from lung tissue collection, featuring Afatinib resistance.

Patient-derived xenograft model for colorectal cancer.

Lymphoma syngeneic model on BALB/c mouse strain with immune cell profiling and RNAseq data available.

Liver cancer syngeneic model on BALB/c mouse strain with immune cell profiling and RNAseq data available.

GEMMs supporting mechanistic studies, pathway biology, and resistance research in genetically defined pancreatic cancer settings.

Pancreatic cancer syngeneic model on C57BL/6 mouse strain with immune cell profiling and RNAseq data available.

Prostate cancer syngeneic model on C57BL/6 mouse strain with immune cell profiling and RNAseq data available.

Patient-derived xenograft model for melanoma.

Colorectal cancer syngeneic model on BALB/c mouse strain with immune cell profiling and RNAseq data available.

Patient-derived xenograft model for metastatic carcinoma.

A proprietary genetic signature discovery and validation platform designed to identify gene signatures that predict patient clinical response and help reduce attrition rates in oncology drug development.

Patient-derived xenograft model for bladder cancer.

Preclinical humanized PBMC mouse models for evaluating novel immuno-oncology agents within a human tumor microenvironment using transient human immunity.

Patient-derived xenograft model for gastric cancer.

Patient-derived xenograft model for kidney cancer.

Patient-derived xenograft model for skin cancer.

Colorectal cancer patient-derived xenograft model with metastatic pathology diagnosis from the liver.

Kidney cancer syngeneic model on BALB/c mouse strain with immune cell profiling and RNAseq data available.

Melanoma syngeneic model on C57BL/6 mouse strain with immune cell profiling and RNAseq data available.

Patient-derived xenograft model for cervical cancer.

Patient-derived xenograft model for lymphoma.

Combines the predictive power of GEMM with an improved operational simplicity, consistency, and growth, similar to syngeneic models for pharmacological research.

Patient-derived xenograft model for gastrointestinal stromal tumor (GIST).

Patient-derived xenograft model for head and neck cancer.

Cell-based assays for drug screening including Cancer Cell Panel Screening, a proprietary high-throughput platform for broad efficacy evaluation.

Breast cancer patient-derived xenograft model with metastatic pathology diagnosis from the right supraclavicular lymph node.

Melanoma syngeneic model on C57BL/6 mouse strain with immune cell profiling and RNAseq data available.

Screening package designed to quantitatively evaluate the efficacy and potency of agents across models representing a heterogeneous patient population.

Colorectal cancer patient-derived xenograft model with metastatic pathology diagnosis from a perihepatic soft tissue lesion.

A high content imaging platform combining 3D models including organoids and spheroids with high content screening, enabling efficient analysis of immuno-oncology therapeutic effects in a physiologically relevant environment.

Patient-derived xenograft model for sarcoma.

Breast cancer patient-derived xenograft model with metastatic pathology diagnosis from the left axillary lymph node.

Breast cancer patient-derived xenograft model with metastatic pathology diagnosis from a left chest wall mass.

Liver cancer syngeneic model on C57BL/6 mouse strain with immune cell profiling and RNAseq data available.

Patient-derived xenograft model for pancreatic cancer.

OMICS and Standard of Care datasets from PDX and organoid models supporting AI drug discovery, biomarker development, and target validation.

Patient-derived xenograft model for prostate cancer.

Colorectal cancer patient-derived xenograft model with metastatic pathology diagnosis from a parasacral mass.

Breast cancer syngeneic model on BALB/c mouse strain with immune cell profiling and RNAseq data available.

Patient-derived xenograft model for ovarian cancer.

Colorectal cancer patient-derived xenograft model with metastatic pathology diagnosis from a perirectal mass.

Esophageal cancer patient-derived xenograft model with metastatic pathology diagnosis from the liver.

Patient-derived xenograft model for adrenal gland cancer.

An online database for cell line and xenograft models, enabling users to search and browse well-curated and detailed profiles for more than 1,000 cancer cell lines and 200 validated in vivo cell line-derived xenograft (CDX) models.

Patient-derived xenograft model for cholangiocarcinoma.

Patient-derived xenograft model for esophageal cancer.

Screening package to rapidly identify lead agents from a library of 10+ compounds using an extensive organoid library.

Patient-derived xenograft model for thyroid cancer.

Patient-derived xenograft model for uterine cancer.

Patient-derived xenograft model for gallbladder cancer.

Colon cancer humanized PBMC mouse model utilizing NOD/SCID or NCG/NOG/NPG strains for evaluating CD3-bispecific antibodies, Anti-PD-1, and Anti-PD-L1.

Lung cancer humanized PBMC mouse model utilizing NCG/NOG/NPG strains.

Integrated, compliant biomarker testing and multiomics analysis from discovery and assay development to clinical validation using CAP-accredited labs.

Lung cancer humanized PBMC mouse model utilizing NCG strains for Anti-PD-1 antibody testing.

Colon cancer humanized PBMC mouse model utilizing NPG and NOD/SCID strains.

Patient-derived xenograft model for acute lymphoblastic leukemia.

Patient-derived xenograft model for mesothelioma.

Lung cancer humanized PBMC mouse model utilizing NCG/NOG/NPG strains for Anti-PD-1 and Anti-PD-L1 antibody testing.

Lymphoma humanized PBMC mouse model utilizing NCG/NOG/NPG strains for CD3-bispecific antibody, Ibrutinib, Anti-PD-1, and Anti-PD-L1 testing.

A cost-effective, high-throughput screening platform allowing rapid screening of over 500 cancer cell lines to provide key information on cytotoxicity and chemotherapeutic potential.

Breast cancer humanized PBMC mouse model utilizing NCG/NOG/NPG animal strains for CD3-bispecific antibody and Herceptin testing.

Patient-derived xenograft model for mixed mullerian cancer.

Esophageal cancer humanized PBMC mouse model utilizing NPG and NOD/SCID strains.

Lung cancer humanized PBMC mouse model utilizing SCID/Beige strains.

Screening package to identify optimal dosing for combination strategies and evaluate multiple strategies to find optimal in vivo dosing combinations.

Esophageal cancer humanized PBMC mouse model utilizing NPG and NOD/SCID strains.

The chimeric human/mouse PD-1 gene consisting of human exon 2 knocked in using CRISPR technology to create homozygous h/mPD-1 Humanized Target Tumor Cells C57BL/6 mice for human anti-PD-1 antibody evaluation.

Patient-derived xenograft model for testical cancer.

Colon cancer humanized PBMC mouse model utilizing NCG/NOG/NPG animal strains for Cetuximab testing.

Colon cancer humanized PBMC mouse model utilizing NCG/NOG/NPG strains for Anti-CD137 antibody testing.

Lymphoma humanized PBMC mouse model utilizing NCG/NOG/NPG strains for Anti-PD-L1 and CD47 BiTE evaluation.

Immunocompetent chimeric mouse models, engineered to express humanized drug targets such as genes encoding for immune checkpoint proteins.

Lymphoma humanized PBMC mouse model utilizing NCG/NOG/NPG strains.

Liver cancer humanized PBMC mouse model utilizing NPG strains.

Lymphoma humanized PBMC mouse model utilizing NCG/NOG/NPG strains.

Study unique immune-related adverse events (irAEs) associated with immunotherapies, using Humanized genetically modified mouse models and Humanized Target Tumor Cells human target knock-in models.

Leukemia humanized PBMC mouse model utilizing NOD/SCID strains.

Single Knock-In mouse model on a C57BL/6 background for immuno-oncology research.

Single Knock-In mouse model on a C57BL/6 background for immuno-oncology research.

An integrated drug discovery platform utilizing CRISPR technology for in vitro and in vivo efficacy studies, enabling stable knockouts/knock-ins and disease modeling.

Assays designed to test the ability of compounds to potentiate migration and infiltration of T cells into tumors, enhance cytotoxic activity, and study interactions with activated immune cells in organoid cultures.

Single Knock-In mouse model on a C57BL/6 background for immuno-oncology research.

Single Knock-In mouse model on a C57BL/6 background for immuno-oncology research.

Crown Bioscience service utilizing 10x Genomics Visium technology to deliver cutting-edge spatial gene expression profiling and whole transcriptome analysis within the context of tissue architecture.

An NGS-based murine targeted panel for immuno-oncology (I/O) and tumor microenvironment (TME) studies, designed to measure 1080 transcripts from a single sample.

Bladder Cancer Tumor Microarrays derived from PDX for H&E and IHC staining, formalin-fixed and embedded in paraffin.

Use our comprehensive tool set including RNAi, gene cloning and stable transfection, RT-PCR and reporter gene assays to determine the biological functions of your cancer target.

Hematology analysis, biofluid chemistry, and biomarker analysis for robust, high-quality data. Use as a standalone service, or as a supplement to in vivo studies.

Electrochemiluminescence technology platform used for Meso Scale Discovery (MSD) biomarker assays.

Clinical chemistry analyzer utilized for high-throughput blood and urine chemistry testing services.